Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CORT 
Corcept Therapeutics Incorporated (CORT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/16/2025: CORT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $138.25
1 Year Target Price $138.25
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.17% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.57B USD | Price to earnings Ratio 62.1 | 1Y Target Price 138.25 |
Price to earnings Ratio 62.1 | 1Y Target Price 138.25 | ||
Volume (30-day avg) 4 | Beta 0.18 | 52 Weeks Range 32.33 - 117.33 | Updated Date 07/15/2025 |
52 Weeks Range 32.33 - 117.33 | Updated Date 07/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 19.55% | Operating Margin (TTM) 2.17% |
Management Effectiveness
Return on Assets (TTM) 9.18% | Return on Equity (TTM) 21.77% |
Valuation
Trailing PE 62.1 | Forward PE 56.82 | Enterprise Value 7400944527 | Price to Sales(TTM) 11.05 |
Enterprise Value 7400944527 | Price to Sales(TTM) 11.05 | ||
Enterprise Value to Revenue 10.8 | Enterprise Value to EBITDA 65.79 | Shares Outstanding 106045000 | Shares Floating 87673513 |
Shares Outstanding 106045000 | Shares Floating 87673513 | ||
Percent Insiders 11.49 | Percent Institutions 79.64 |
Upturn AI SWOT
Corcept Therapeutics Incorporated
Company Overview
History and Background
Corcept Therapeutics Incorporated was founded in 1998 and focuses on the discovery, development, and commercialization of drugs to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of cortisol. Its initial focus was on Cushing's syndrome, a rare endocrine disorder.
Core Business Areas
- Cushing's Syndrome: Development and commercialization of medications to treat Cushing's syndrome, a condition caused by prolonged exposure to high levels of cortisol.
- Oncology: Research and development of cortisol modulation therapies for various cancers.
- Metabolic Diseases: Exploring the potential of cortisol modulation in treating metabolic disorders.
Leadership and Structure
Joseph K. Belanoff, M.D. serves as the Chief Executive Officer. The company has a standard corporate structure with departments focusing on research and development, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- Korlym (mifepristone): Korlym is Corcept's primary product, used to treat Cushing's syndrome. While specific market share data fluctuates, Korlym holds a significant portion of the Cushing's syndrome medication market. Revenue from Korlym accounts for the majority of Corcept's revenue. Competitors are limited due to Korlym's unique mechanism of action, though alternative treatments for Cushing's exist, such as surgery, radiation, and other medications like Signifor (pasireotide) and Isturisa (osilodrostat).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The focus is on developing and commercializing novel therapies for various diseases. Market trends include personalized medicine, advancements in biotechnology, and increasing regulatory scrutiny.
Positioning
Corcept is a specialty pharmaceutical company focused on cortisol modulation. Its competitive advantage lies in its expertise in this area and its established presence in the Cushing's syndrome market.
Total Addressable Market (TAM)
The global Cushing's syndrome market is estimated to be several hundred million USD. Corcept is well positioned, with potential to expand beyond Cushing's to other cortisol-related diseases. The TAM for oncology and metabolic disease applications is potentially much larger.
Upturn SWOT Analysis
Strengths
- Established product in a niche market (Korlym)
- Expertise in cortisol modulation
- Strong intellectual property portfolio
- Positive cash flow
Weaknesses
- Reliance on a single product (Korlym)
- Potential for generic competition
- Lawsuits and patent challenges
- Concentrated revenue source
Opportunities
- Expansion into new indications (oncology, metabolic diseases)
- Development of next-generation cortisol modulators
- Partnerships and collaborations
- Geographic expansion
Threats
- Generic competition
- Regulatory hurdles
- Patent invalidation
- Competition from other Cushing's treatments
Competitors and Market Share
Key Competitors
- Novartis (NVS)
- Recordati Rare Diseases (No US Stock Symbol)
- Millendo Therapeutics (MLNDQ) (Bankrupt)
Competitive Landscape
Corcept holds a dominant position in the Cushing's syndrome medication market with Korlym. Novartis competes with Signifor (pasireotide). The recent bankruptcy of Millendo Therapeutics and the acquisition of Isturisa by Recordati have altered the competitive landscape.
Growth Trajectory and Initiatives
Historical Growth: Corcept's growth has been primarily driven by increasing sales of Korlym and expanding its pipeline of cortisol modulation therapies.
Future Projections: Analyst estimates project continued revenue growth for Korlym and potential upside from its oncology and metabolic disease programs. However, projections are subject to regulatory approvals and clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing its oncology and metabolic disease pipeline, seeking regulatory approvals for new indications, and defending its intellectual property.
Summary
Corcept Therapeutics is a specialty pharmaceutical company with a strong position in the Cushing's syndrome market due to its drug, Korlym. The company's reliance on a single product represents a risk. Corcept is actively pursuing expansion into oncology and metabolic diseases to diversify its revenue streams, although any generic competition would pose a significant threat. A strong balance sheet and positive cash flow provide a solid foundation for future growth, but lawsuits related to patents do pose a risk to revenue and future potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corcept Therapeutics Incorporated
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2004-04-14 | Co-Founder, President, CEO & Director Dr. Joseph K. Belanoff M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 500 | Website https://www.corcept.com |
Full time employees 500 | Website https://www.corcept.com | ||
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.